表皮生长因子受体家族在骨肉瘤中的研究进展  

The role of epidermal growth factor receptor family in osteosarcoma

作　　者：王生淋 余凤强 林建华[1] Wang Shenglin;Yu Fengqiang;Lin Jianhua(Department of Orthopedics, the First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, Chin)

机构地区：[1]福建医科大学附属第一医院骨科,福州350005

出　　处：《中华实验外科杂志》2018年第4期793-798,共6页Chinese Journal of Experimental Surgery

基　　金：国家自然科学基金（31571292）

摘　　要：骨肉瘤（Osteosarcoma）是最常见的原发恶性骨肿瘤，其恶性程度高、预后差，严重威胁儿童和青少年的健康。表皮生长因子受体（EGFR）家族属于Ⅰ型跨膜酪氨酸激酶受体，其表达能够抑制肿瘤细胞凋亡，促进肿瘤细胞增殖、血管生成和远处转移。目前国内外有关EGFR家族与骨肉瘤进展的研究十分有限且存在较大争议。本文将对EGFR家族表达与骨肉瘤进展相关性以及EGFR抑制剂在骨肉瘤治疗中的应用作综合性阐述。Osteosarcoma, the most common primary bone tumor with high malignancy and poor prognosis, seriously threatens the health of children and adolescents. Epidermal growth factor receptor （EGFR） familythe type I transmembrane receptor tyrosine kinase - can promote oncogenic transformation via cell survival, proliferation, angiogenesis and metastasis. Overseas and domestic researches on the effect of EGFR family in osteosarcoma are rare and re- main controversial. The purpose of this article was to review the expression of EGFR family in the development of osteo- sarcoma and the application of inhibitors of EGFR family in the treatment of osteosarcoma.

关 键 词：表皮生长因子受体 骨肉瘤 酪氨酸激酶受体 

分 类 号：R738.1[医药卫生—肿瘤]